Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02309411 · ClinicalTrials.gov registry record · Phase 2
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
A Phase 2 study of Venous Thromboembolism, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 20
- Study locations
NCT02309411 is a Phase 2 study of Venous Thromboembolism that has completed, run by Bayer. The registered enrollment target is 46 participants, below the 6,295-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02309411, a Phase 2 study of Venous Thromboembolism, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. Safety will be assessed by looking at the incidence and types of bleeding events. There will also be a check for worsening of blood clots.
Conditions Studied
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
Study Locations (20)
Other
- - Vienna
- - São Paulo
- - Budapest
- - Jerusalem
- - Ramat Gan
- - Nijmegen
- - Gdansk
- - Olsztyn
Florida
- - Gainesville
- - Pensacola
Georgia
- Children's Healthcare of Atlanta - Atlanta
Illinois
- - Chicago
Indiana
- - Indianapolis
Victoria
- - Parkville
São Paulo
- - São Paulo
Ontario
- - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2015-01-15 |
| Est. Completion | 2017-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02309411
The ClinicalTrials.gov registry entry for NCT02309411 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,295-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (99% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT02309411 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02309411 about?
NCT02309411 is a clinical study titled "EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis". The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. Safety will be assessed by looking at the incidence and types of bleeding events. There will also be a check for worsening of blood clots.
What is the current status of trial NCT02309411?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2015-01-15. Estimated completion is 2017-04-05.
What conditions does trial NCT02309411 study?
This clinical trial studies the following conditions: Venous Thromboembolism.
What interventions are being tested in trial NCT02309411?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG).
Who is sponsoring clinical trial NCT02309411?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02309411 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Indiana, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
RECRUITING · Phase 2
-
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
ACTIVE NOT RECRUITING · Phase 2
-
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
COMPLETED · Phase 2
-
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
COMPLETED · Phase 2
-
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.